ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline is betting on the potential of deuterium-containing drugs through a collaboration with Concert Pharmaceuticals. The Lexington, Mass.-based biotech firm replaces the hydrogen atoms in a molecule with deuterium, which forms a stronger bond with carbon. The company expects the modification will improve the metabolic properties of drugs. GSK will make a $16.7 million investment in Concert and pay it an $18.3 million up-front fee. It will also make up to $1 billion in milestones payments. In exchange, Concert will provide access to three compounds in the early stages of development, including a version of Bristol-Myers Squibb's HIV protease inhibitor Reyataz. Concert also will make deuterium-modified versions of three products in the GSK pipeline.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter